Evidence map›Paper›PMID 21740967›Full record

ReviewCellular signalling2011

The exquisite regulation of PLD2 by a wealth of interacting proteins: S6K, Grb2, Sos, WASp and Rac2 (and a surprise discovery: PLD2 is a GEF).

Julian Gomez-Cambronero

Open access · greenAbstract readReview
In one paragraph

Review in Cellular signalling, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Phosphatidic acid and neurotransmission.Advances in biological regulation · 2017
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Thematic minireview series on phospholipase D and cancer.The Journal of biological chemistry · 2014
    Article
  16. The Concise Guide to PHARMACOLOGY 2013/14: enzymes.British journal of pharmacology · 2013
    Article
  17. Article
  18. Article
  19. Article
  20. Phospholipase signalling networks in cancer.Nature reviews. Cancer · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Julian Gomez-CambroneroDepartment of Biochemistry and Molecular Biology, Wright State University School of Medicine, Dayton, OH 45435, USA. julian.cambronero@wright.edu
Wright State University · US

Funding

PLD2, as a GEF or as a Lipase, is Central to Leukocyte ChemotaxisR01HL056653 · NHLBI · WRIGHT STATE UNIVERSITY · PI CAMBRONERO, JULIAN G. · 2004 to 2016
$4.0M
SIGNAL TRANSDUCTION IN NEUTROPHIL MEDIATED HEART INJURYR29HL056653 · NHLBI · WRIGHT STATE UNIVERSITY · PI GOMEZ-CAMBRONERO, JULIAN · 1998 to 2002
$301k
NHLBI NIH HHS HL056653NHLBI NIH HHS R01 HL056653NHLBI NIH HHS R29 HL056653
6 · The paper itself

Abstract

Phospholipase D (PLD) catalyzes the conversion of the membrane phospholipid phosphatidylcholine to choline and phosphatidic acid (PA). PLD's mission in the cell is two-fold: phospholipid turnover with maintenance of the structural integrity of cellular/intracellular membranes and cell signaling through PA and its metabolites. Precisely, through its product of the reaction, PA, PLD has been implicated in a variety of physiological cellular functions, such as intracellular protein trafficking, cytoskeletal dynamics, chemotaxis of leukocytes and cell proliferation. The catalytic (HKD) and regulatory (PH and PX) domains were studied in detail in the PLD1 isoform, but PLD2 was traditionally studied in lesser detail and much less was known about its regulation. Our laboratory has been focusing on the study of PLD2 regulation in mammalian cells. Over the past few years, we have reported, in regards to the catalytic action of PLD, that PA is a chemoattractant agent that binds to and signals inside the cell through the ribosomal S6 kinases (S6K). Regarding the regulatory domains of PLD2, we have reported the discovery of the PLD2 interaction with Grb2 via Y169 in the PX domain, and further association to Sos, which results in an increase of de novo DNA synthesis and an interaction (also with Grb2) via the adjacent residue Y179, leading to the regulation of cell ruffling, chemotaxis and phagocytosis of leukocytes. We also present the complex regulation by tyrosine phosphorylation by epidermal growth factor receptor (EGF-R), Janus Kinase 3 (JAK3) and Src and the role of phosphatases. Recently, there is evidence supporting a new level of regulation of PLD2 at the PH domain, by the discovery of CRIB domains and a Rac2-PLD2 interaction that leads to a dual (positive and negative) effect on its enzymatic activity. Lastly, we review the surprising finding of PLD2 acting as a GEF. A phospholipase such as PLD that exists already in the cell membrane that acts directly on Rac allows a quick response of the cell without intermediary signaling molecules. This provides only the latest level of PLD2 regulation in a field that promises newer and exciting advances in the next few years.

Indexed as

Amino Acid SequenceAnimalsCell Physiological PhenomenaGene Expression RegulationGRB2 Adaptor ProteinGuanine Nucleotide Exchange FactorsHumansMolecular Sequence DataPhosphatidic AcidsPhospholipase DProtein BindingProtein Interaction Domains and MotifsProtein IsoformsProtein-Tyrosine KinasesProtein Tyrosine PhosphatasesRAC2 GTP-Binding ProteinGRB2 Adaptor ProteinGuanine Nucleotide Exchange FactorsPhosphatidic AcidsPhospholipase Dphospholipase D2Protein IsoformsProtein-Tyrosine KinasesProtein Tyrosine PhosphatasesRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsRibosomal Protein S6 Kinases, 90-kDaSon of Sevenless Protein, DrosophilaWiskott-Aldrich Syndrome Protein

Identifiers

PMID21740967
PMCPMC3204931
OpenAlexW2090242276

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.